Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,889
archived clinical trials in
Blood Cancer

T-Reg Cell Kinetics for Patients Receiving Stem Cell Transplant
T-Regulatory Cell Kinetics for Patients Receiving Alemtuzamb and Undergoing Stem Cell Transplantation From HLA Mismatched-Related, or HLA Matched, or One Antigen Mismatched-Unrelated Donors
Status: Enrolling
Updated:  4/10/2012
Texas Children's Hospital
mi
from
Houston, TX
T-Reg Cell Kinetics for Patients Receiving Stem Cell Transplant
T-Regulatory Cell Kinetics for Patients Receiving Alemtuzamb and Undergoing Stem Cell Transplantation From HLA Mismatched-Related, or HLA Matched, or One Antigen Mismatched-Unrelated Donors
Status: Enrolling
Updated: 4/10/2012
Texas Children's Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
T-Reg Cell Kinetics for Patients Receiving Stem Cell Transplant
T-Regulatory Cell Kinetics for Patients Receiving Alemtuzamb and Undergoing Stem Cell Transplantation From HLA Mismatched-Related, or HLA Matched, or One Antigen Mismatched-Unrelated Donors
Status: Enrolling
Updated:  4/10/2012
Baylor College of Medicine
mi
from
Houston, TX
T-Reg Cell Kinetics for Patients Receiving Stem Cell Transplant
T-Regulatory Cell Kinetics for Patients Receiving Alemtuzamb and Undergoing Stem Cell Transplantation From HLA Mismatched-Related, or HLA Matched, or One Antigen Mismatched-Unrelated Donors
Status: Enrolling
Updated: 4/10/2012
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Tacrolimus and ATG as GVHD Prophylaxis in Patients Undergoing Related Donor HSCT
A Phase II Study of Tacrolimus and Thymoglobulin, as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Related Donor Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  4/30/2012
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Tacrolimus and ATG as GVHD Prophylaxis in Patients Undergoing Related Donor HSCT
A Phase II Study of Tacrolimus and Thymoglobulin, as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Related Donor Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 4/30/2012
Barbara Ann Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
A Trial of TBL-12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma
A Phase II Trial of TBL-12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma
Status: Enrolling
Updated:  5/2/2012
New York University School of Medicine, Clinical Cancer Center
mi
from
New York, NY
A Trial of TBL-12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma
A Phase II Trial of TBL-12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma
Status: Enrolling
Updated: 5/2/2012
New York University School of Medicine, Clinical Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies
Phase II Pilot Efficacy Trial of the Combination Regimen Oncaspar/Doxil/Decadron (ODD) in Patients With Refractory Lymphoid Malignancies
Status: Enrolling
Updated:  5/11/2012
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies
Phase II Pilot Efficacy Trial of the Combination Regimen Oncaspar/Doxil/Decadron (ODD) in Patients With Refractory Lymphoid Malignancies
Status: Enrolling
Updated: 5/11/2012
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant
Pilot Study of Mechanical Stimulation for Prevention of Hematopoietic Cell Transplant Associated Bone Density Loss
Status: Archived
Updated:  5/11/2012
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant
Pilot Study of Mechanical Stimulation for Prevention of Hematopoietic Cell Transplant Associated Bone Density Loss
Status: Archived
Updated: 5/11/2012
Roswell Park Cancer Institute
mi
from
Buffalo, NY
A Study Evaluating Hypotension and Autonomic Nervous System Dysfunction in Multiple Myeloma (MM) Patients
A Pilot Study Evaluating Hypotension and Autonomic Nervous System Dysfunction After Therapy With Bortezomib-containing Regimens in Subjects With Multiple Myeloma
Status: Enrolling
Updated:  5/15/2012
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
A Study Evaluating Hypotension and Autonomic Nervous System Dysfunction in Multiple Myeloma (MM) Patients
A Pilot Study Evaluating Hypotension and Autonomic Nervous System Dysfunction After Therapy With Bortezomib-containing Regimens in Subjects With Multiple Myeloma
Status: Enrolling
Updated: 5/15/2012
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
A Study Evaluating Hypotension and Autonomic Nervous System Dysfunction in Multiple Myeloma (MM) Patients
A Pilot Study Evaluating Hypotension and Autonomic Nervous System Dysfunction After Therapy With Bortezomib-containing Regimens in Subjects With Multiple Myeloma
Status: Enrolling
Updated:  5/15/2012
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
A Study Evaluating Hypotension and Autonomic Nervous System Dysfunction in Multiple Myeloma (MM) Patients
A Pilot Study Evaluating Hypotension and Autonomic Nervous System Dysfunction After Therapy With Bortezomib-containing Regimens in Subjects With Multiple Myeloma
Status: Enrolling
Updated: 5/15/2012
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
Cyclophosphamide and Pulse Dexamethasone With Rapamycin or Hydroxychloroquine
A Pilot Study of Infusional Cyclophosphamide and Pulse Dexamethasone With Rapamycin or Hydroxychloroquine in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  5/17/2012
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Cyclophosphamide and Pulse Dexamethasone With Rapamycin or Hydroxychloroquine
A Pilot Study of Infusional Cyclophosphamide and Pulse Dexamethasone With Rapamycin or Hydroxychloroquine in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 5/17/2012
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Probiotic Use in Children Undergoing Hematopoietic Stem Cell Transplantation (HSCT) - A Pilot Study
A Limited Institution Pilot Trial Evaluating the Safety of Administering the Probiotic, Lactobacillus Plantarum, to Children and Adolescents Undergoing Allogenic Hematopoietic Stem Cell Transplantation (HSCT)
Status: Enrolling
Updated:  5/18/2012
All Children's Hospital
mi
from
St. Petersburg, FL
Probiotic Use in Children Undergoing Hematopoietic Stem Cell Transplantation (HSCT) - A Pilot Study
A Limited Institution Pilot Trial Evaluating the Safety of Administering the Probiotic, Lactobacillus Plantarum, to Children and Adolescents Undergoing Allogenic Hematopoietic Stem Cell Transplantation (HSCT)
Status: Enrolling
Updated: 5/18/2012
All Children's Hospital
mi
from
St. Petersburg, FL
Click here to add this to my saved trials
Probiotic Use in Children Undergoing Hematopoietic Stem Cell Transplantation (HSCT) - A Pilot Study
A Limited Institution Pilot Trial Evaluating the Safety of Administering the Probiotic, Lactobacillus Plantarum, to Children and Adolescents Undergoing Allogenic Hematopoietic Stem Cell Transplantation (HSCT)
Status: Enrolling
Updated:  5/18/2012
Columbia Universtiy Medical Center
mi
from
New York, NY
Probiotic Use in Children Undergoing Hematopoietic Stem Cell Transplantation (HSCT) - A Pilot Study
A Limited Institution Pilot Trial Evaluating the Safety of Administering the Probiotic, Lactobacillus Plantarum, to Children and Adolescents Undergoing Allogenic Hematopoietic Stem Cell Transplantation (HSCT)
Status: Enrolling
Updated: 5/18/2012
Columbia Universtiy Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Fixed Dose Radioimmunotherapy (Zevalin, Yttrium-90 Ibritumomab Tiuxetan) for Patients With Incomplete Response to Chemotherapy Prior to Autologous Stem Cell Transplant for Multiple Myeloma
A Phase II, Safety and Efficacy Study of Fixed Dose Radioimmunotherapy (Zevalin, Yttrium-90 Ibritumomab Tiuxetan) for Patients With Incomplete Response to Chemotherapy Prior to Autologous Stem Cell Transplant for Multiple Myeloma
Status: Enrolling
Updated:  5/29/2012
Tufts Medical Center
mi
from
Boston, MA
A Study of Fixed Dose Radioimmunotherapy (Zevalin, Yttrium-90 Ibritumomab Tiuxetan) for Patients With Incomplete Response to Chemotherapy Prior to Autologous Stem Cell Transplant for Multiple Myeloma
A Phase II, Safety and Efficacy Study of Fixed Dose Radioimmunotherapy (Zevalin, Yttrium-90 Ibritumomab Tiuxetan) for Patients With Incomplete Response to Chemotherapy Prior to Autologous Stem Cell Transplant for Multiple Myeloma
Status: Enrolling
Updated: 5/29/2012
Tufts Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia
Safety and Efficacy of Gemtuzumab Ozogamicin (Mylotarg®) as for Treatment of Patients With CD33-Positive Acute Myeloid Leukemia (AML)
Status: Archived
Updated:  5/29/2012
Comprehensive Cancer Center of Wake Forest University
mi
from
Winston-Salem, NC
Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia
Safety and Efficacy of Gemtuzumab Ozogamicin (Mylotarg®) as for Treatment of Patients With CD33-Positive Acute Myeloid Leukemia (AML)
Status: Archived
Updated: 5/29/2012
Comprehensive Cancer Center of Wake Forest University
mi
from
Winston-Salem, NC
IMGN901 in Combination With Lenalidomide and Dexamethasone
An Open-Label Phase I Study of Bb-10901 (IMGN901, huN901-DM10 in Combination With Lenalidomide and Dexamethasone in Patients With CD56-positive Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  5/30/2012
University of Southern California
mi
from
Los Angeles, CA
IMGN901 in Combination With Lenalidomide and Dexamethasone
An Open-Label Phase I Study of Bb-10901 (IMGN901, huN901-DM10 in Combination With Lenalidomide and Dexamethasone in Patients With CD56-positive Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 5/30/2012
University of Southern California
mi
from
Los Angeles, CA
Click here to add this to my saved trials
IMGN901 in Combination With Lenalidomide and Dexamethasone
An Open-Label Phase I Study of Bb-10901 (IMGN901, huN901-DM10 in Combination With Lenalidomide and Dexamethasone in Patients With CD56-positive Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  5/30/2012
Comprehensive Cancer Center of the Desert
mi
from
Palm Springs, CA
IMGN901 in Combination With Lenalidomide and Dexamethasone
An Open-Label Phase I Study of Bb-10901 (IMGN901, huN901-DM10 in Combination With Lenalidomide and Dexamethasone in Patients With CD56-positive Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 5/30/2012
Comprehensive Cancer Center of the Desert
mi
from
Palm Springs, CA
Click here to add this to my saved trials
IMGN901 in Combination With Lenalidomide and Dexamethasone
An Open-Label Phase I Study of Bb-10901 (IMGN901, huN901-DM10 in Combination With Lenalidomide and Dexamethasone in Patients With CD56-positive Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  5/30/2012
Florida Cancer Specialists
mi
from
Fort Myers, FL
IMGN901 in Combination With Lenalidomide and Dexamethasone
An Open-Label Phase I Study of Bb-10901 (IMGN901, huN901-DM10 in Combination With Lenalidomide and Dexamethasone in Patients With CD56-positive Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 5/30/2012
Florida Cancer Specialists
mi
from
Fort Myers, FL
Click here to add this to my saved trials
IMGN901 in Combination With Lenalidomide and Dexamethasone
An Open-Label Phase I Study of Bb-10901 (IMGN901, huN901-DM10 in Combination With Lenalidomide and Dexamethasone in Patients With CD56-positive Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  5/30/2012
Roswell Park Cancer Institute
mi
from
Buffalo, NY
IMGN901 in Combination With Lenalidomide and Dexamethasone
An Open-Label Phase I Study of Bb-10901 (IMGN901, huN901-DM10 in Combination With Lenalidomide and Dexamethasone in Patients With CD56-positive Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 5/30/2012
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
IMGN901 in Combination With Lenalidomide and Dexamethasone
An Open-Label Phase I Study of Bb-10901 (IMGN901, huN901-DM10 in Combination With Lenalidomide and Dexamethasone in Patients With CD56-positive Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  5/30/2012
Weill Medical College
mi
from
New York, NY
IMGN901 in Combination With Lenalidomide and Dexamethasone
An Open-Label Phase I Study of Bb-10901 (IMGN901, huN901-DM10 in Combination With Lenalidomide and Dexamethasone in Patients With CD56-positive Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 5/30/2012
Weill Medical College
mi
from
New York, NY
Click here to add this to my saved trials
IMGN901 in Combination With Lenalidomide and Dexamethasone
An Open-Label Phase I Study of Bb-10901 (IMGN901, huN901-DM10 in Combination With Lenalidomide and Dexamethasone in Patients With CD56-positive Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  5/30/2012
Duke Univ Med Ctr
mi
from
Durham, NC
IMGN901 in Combination With Lenalidomide and Dexamethasone
An Open-Label Phase I Study of Bb-10901 (IMGN901, huN901-DM10 in Combination With Lenalidomide and Dexamethasone in Patients With CD56-positive Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 5/30/2012
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
IMGN901 in Combination With Lenalidomide and Dexamethasone
An Open-Label Phase I Study of Bb-10901 (IMGN901, huN901-DM10 in Combination With Lenalidomide and Dexamethasone in Patients With CD56-positive Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  5/30/2012
Fox Chase Cancer Center
mi
from
Philadephia, PA
IMGN901 in Combination With Lenalidomide and Dexamethasone
An Open-Label Phase I Study of Bb-10901 (IMGN901, huN901-DM10 in Combination With Lenalidomide and Dexamethasone in Patients With CD56-positive Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 5/30/2012
Fox Chase Cancer Center
mi
from
Philadephia, PA
Click here to add this to my saved trials
IMGN901 in Combination With Lenalidomide and Dexamethasone
An Open-Label Phase I Study of Bb-10901 (IMGN901, huN901-DM10 in Combination With Lenalidomide and Dexamethasone in Patients With CD56-positive Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  5/30/2012
Sarah Cannon Research Institute
mi
from
Nashville, TN
IMGN901 in Combination With Lenalidomide and Dexamethasone
An Open-Label Phase I Study of Bb-10901 (IMGN901, huN901-DM10 in Combination With Lenalidomide and Dexamethasone in Patients With CD56-positive Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 5/30/2012
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
IMGN901 in Combination With Lenalidomide and Dexamethasone
An Open-Label Phase I Study of Bb-10901 (IMGN901, huN901-DM10 in Combination With Lenalidomide and Dexamethasone in Patients With CD56-positive Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated:  5/30/2012
CTRC at University of Texas Health Science Center
mi
from
San Antonio, TX
IMGN901 in Combination With Lenalidomide and Dexamethasone
An Open-Label Phase I Study of Bb-10901 (IMGN901, huN901-DM10 in Combination With Lenalidomide and Dexamethasone in Patients With CD56-positive Relapsed or Relapsed/Refractory Multiple Myeloma
Status: Enrolling
Updated: 5/30/2012
CTRC at University of Texas Health Science Center
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)
A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and SLL
Status: Enrolling
Updated:  5/31/2012
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)
A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and SLL
Status: Enrolling
Updated: 5/31/2012
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemia
A Phase II Trial of Revlimid® as Consolidation Treatment of Residual Disease in Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated:  5/31/2012
UC San Diego Moores Cancer Center
mi
from
La Jolla, CA
Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemia
A Phase II Trial of Revlimid® as Consolidation Treatment of Residual Disease in Patients With Chronic Lymphocytic Leukemia (CLL)
Status: Enrolling
Updated: 5/31/2012
UC San Diego Moores Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
MLN8237 in Adults With Nonhematological Malignancies, Followed by MLN8237 in Lung, Breast, Head and Neck or Gastroesophageal Malignancies
A Phase 1 Dose Escalation Study of MLN8237, an Aurora A Kinase Inhibitor, in Adult Patients With Nonhematological Malignancies, Followed by a Phase 2 of MLN8237 in Lung, Breast, Head and Neck, or Gastroesophageal Malignancies
Status: Enrolling
Updated:  6/18/2012
Medical Oncology Hematology, Stamford Hospital
mi
from
Stamford, CT
MLN8237 in Adults With Nonhematological Malignancies, Followed by MLN8237 in Lung, Breast, Head and Neck or Gastroesophageal Malignancies
A Phase 1 Dose Escalation Study of MLN8237, an Aurora A Kinase Inhibitor, in Adult Patients With Nonhematological Malignancies, Followed by a Phase 2 of MLN8237 in Lung, Breast, Head and Neck, or Gastroesophageal Malignancies
Status: Enrolling
Updated: 6/18/2012
Medical Oncology Hematology, Stamford Hospital
mi
from
Stamford, CT
Click here to add this to my saved trials
MLN8237 in Adults With Nonhematological Malignancies, Followed by MLN8237 in Lung, Breast, Head and Neck or Gastroesophageal Malignancies
A Phase 1 Dose Escalation Study of MLN8237, an Aurora A Kinase Inhibitor, in Adult Patients With Nonhematological Malignancies, Followed by a Phase 2 of MLN8237 in Lung, Breast, Head and Neck, or Gastroesophageal Malignancies
Status: Enrolling
Updated:  6/18/2012
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
MLN8237 in Adults With Nonhematological Malignancies, Followed by MLN8237 in Lung, Breast, Head and Neck or Gastroesophageal Malignancies
A Phase 1 Dose Escalation Study of MLN8237, an Aurora A Kinase Inhibitor, in Adult Patients With Nonhematological Malignancies, Followed by a Phase 2 of MLN8237 in Lung, Breast, Head and Neck, or Gastroesophageal Malignancies
Status: Enrolling
Updated: 6/18/2012
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
MLN8237 in Adults With Nonhematological Malignancies, Followed by MLN8237 in Lung, Breast, Head and Neck or Gastroesophageal Malignancies
A Phase 1 Dose Escalation Study of MLN8237, an Aurora A Kinase Inhibitor, in Adult Patients With Nonhematological Malignancies, Followed by a Phase 2 of MLN8237 in Lung, Breast, Head and Neck, or Gastroesophageal Malignancies
Status: Enrolling
Updated:  6/18/2012
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
MLN8237 in Adults With Nonhematological Malignancies, Followed by MLN8237 in Lung, Breast, Head and Neck or Gastroesophageal Malignancies
A Phase 1 Dose Escalation Study of MLN8237, an Aurora A Kinase Inhibitor, in Adult Patients With Nonhematological Malignancies, Followed by a Phase 2 of MLN8237 in Lung, Breast, Head and Neck, or Gastroesophageal Malignancies
Status: Enrolling
Updated: 6/18/2012
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Dasatinib Combo With SMO Inhibitor (BMS-833923)
Dasatinib (BMS-354825) Combined With SMO Inhibitor (BMS-833923; XL139) in CML With Resistance or Suboptimal Response to a Prior TKI
Status: Enrolling
Updated:  6/18/2012
University of California Medical Center
mi
from
Los Angeles, CA
Dasatinib Combo With SMO Inhibitor (BMS-833923)
Dasatinib (BMS-354825) Combined With SMO Inhibitor (BMS-833923; XL139) in CML With Resistance or Suboptimal Response to a Prior TKI
Status: Enrolling
Updated: 6/18/2012
University of California Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Dasatinib Combo With SMO Inhibitor (BMS-833923)
Dasatinib (BMS-354825) Combined With SMO Inhibitor (BMS-833923; XL139) in CML With Resistance or Suboptimal Response to a Prior TKI
Status: Enrolling
Updated:  6/18/2012
Sidney Kimmel Cancer Center At Johns Hopkins
mi
from
Baltimore, MD
Dasatinib Combo With SMO Inhibitor (BMS-833923)
Dasatinib (BMS-354825) Combined With SMO Inhibitor (BMS-833923; XL139) in CML With Resistance or Suboptimal Response to a Prior TKI
Status: Enrolling
Updated: 6/18/2012
Sidney Kimmel Cancer Center At Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Dasatinib Combo With SMO Inhibitor (BMS-833923)
Dasatinib (BMS-354825) Combined With SMO Inhibitor (BMS-833923; XL139) in CML With Resistance or Suboptimal Response to a Prior TKI
Status: Enrolling
Updated:  6/18/2012
University of Michigan Health System
mi
from
Ann Arbor, MI
Dasatinib Combo With SMO Inhibitor (BMS-833923)
Dasatinib (BMS-354825) Combined With SMO Inhibitor (BMS-833923; XL139) in CML With Resistance or Suboptimal Response to a Prior TKI
Status: Enrolling
Updated: 6/18/2012
University of Michigan Health System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Dasatinib Combo With SMO Inhibitor (BMS-833923)
Dasatinib (BMS-354825) Combined With SMO Inhibitor (BMS-833923; XL139) in CML With Resistance or Suboptimal Response to a Prior TKI
Status: Enrolling
Updated:  6/18/2012
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Dasatinib Combo With SMO Inhibitor (BMS-833923)
Dasatinib (BMS-354825) Combined With SMO Inhibitor (BMS-833923; XL139) in CML With Resistance or Suboptimal Response to a Prior TKI
Status: Enrolling
Updated: 6/18/2012
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms
Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol NSC 649890) in Patients With Recurrent or Refractory Indolent B-Cell Neoplasms
Status: Enrolling
Updated:  6/22/2012
H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
mi
from
Tampa, FL
Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms
Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol NSC 649890) in Patients With Recurrent or Refractory Indolent B-Cell Neoplasms
Status: Enrolling
Updated: 6/22/2012
H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
mi
from
Tampa, FL
Click here to add this to my saved trials
Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms
Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol NSC 649890) in Patients With Recurrent or Refractory Indolent B-Cell Neoplasms
Status: Enrolling
Updated:  6/22/2012
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms
Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol NSC 649890) in Patients With Recurrent or Refractory Indolent B-Cell Neoplasms
Status: Enrolling
Updated: 6/22/2012
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated:  6/29/2012
Phoenix Children's Hospital
mi
from
Phoenix, AZ
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated: 6/29/2012
Phoenix Children's Hospital
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated:  6/29/2012
City of Hope
mi
from
Upper San Gabriel Valley, CA
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated: 6/29/2012
City of Hope
mi
from
Upper San Gabriel Valley, CA
Click here to add this to my saved trials
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated:  6/29/2012
Miller Children's Hospital
mi
from
Long Beach, CA
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated: 6/29/2012
Miller Children's Hospital
mi
from
Long Beach, CA
Click here to add this to my saved trials
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated:  6/29/2012
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated: 6/29/2012
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated:  6/29/2012
Oakland Children's Hospital
mi
from
Oakland, CA
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated: 6/29/2012
Oakland Children's Hospital
mi
from
Oakland, CA
Click here to add this to my saved trials
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated:  6/29/2012
Stanford Univ Med Ctr
mi
from
Stanford, CA
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated: 6/29/2012
Stanford Univ Med Ctr
mi
from
Stanford, CA
Click here to add this to my saved trials
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated:  6/29/2012
UCSF School of Medicine
mi
from
San Francisco, CA
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated: 6/29/2012
UCSF School of Medicine
mi
from
San Francisco, CA
Click here to add this to my saved trials
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated:  6/29/2012
University of Miami Cancer Center
mi
from
Miami, FL
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated: 6/29/2012
University of Miami Cancer Center
mi
from
Miami, FL
Click here to add this to my saved trials
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated:  6/29/2012
Children's Healthcare of Atlanta/Emory University
mi
from
Atlanta, GA
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated: 6/29/2012
Children's Healthcare of Atlanta/Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated:  6/29/2012
Childrens Memorial
mi
from
Chicago, IL
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated: 6/29/2012
Childrens Memorial
mi
from
Chicago, IL
Click here to add this to my saved trials
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated:  6/29/2012
Johns Hopkins University
mi
from
Baltimore, MD
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated: 6/29/2012
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated:  6/29/2012
Dana Farber
mi
from
Boston, MA
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated: 6/29/2012
Dana Farber
mi
from
Boston, MA
Click here to add this to my saved trials
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated:  6/29/2012
C.S Mott Children's Hospital
mi
from
Ann Arbor, MI
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated: 6/29/2012
C.S Mott Children's Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated:  6/29/2012
Childrens Hospital & Clinics of Minnesota
mi
from
Minneapolis, MN
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated: 6/29/2012
Childrens Hospital & Clinics of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated:  6/29/2012
University of Minnesota Children's Hospital
mi
from
Minneapolis, MN
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated: 6/29/2012
University of Minnesota Children's Hospital
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated:  6/29/2012
Children's Hospital New York-Presbyterian
mi
from
New York, NY
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated: 6/29/2012
Children's Hospital New York-Presbyterian
mi
from
New York, NY
Click here to add this to my saved trials
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated:  6/29/2012
New York University Medical Center
mi
from
New York, NY
Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia
Clofarabine With Cytarabine for MRD Positive Leukemia
Status: Enrolling
Updated: 6/29/2012
New York University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials